AUTOLOGOUS BONE MARROW TRANSPLANTS--BREAST/OVARY CANCER

自体骨髓移植——乳腺癌/卵巢癌

• 批准号: 3094246
• 负责人: WILLIAM P PETERS
• 金额: $ 58.99万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-06-01 至 1997-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3094246
• 关键词: autologous transplantation; bone marrow transplantation; breast neoplasms; combination cancer therapy; human subject; neoplasm /cancer chemotherapy; ovary neoplasms

This program project grant application applies for continued funding for PPG CA-47741 for studies of high dose chemotherapy in autologous bone marrow support in the treatment of breast and ovarian cancer. The program consists of four projects and three core activities which are highly interrelated, dependent and interactive. In Project IA we propose to (1) complete the prospective randomized, comparative trials in Stage IV and Stage Il breast cancer begun as funded under the first application and (2) extend the use of high dose chemotherapy and autologous bone marrow support in three ways: (a) to apply high dose therapy to patients with primary breast cancer involving four to nine axillary nodes and (b) to patients with bone only disease in a randomized comparative trial; (c) to explore the use of a second high-dose chemotherapy regimen used in tandem. In Project lB, we evaluate the role of high-dose chemotherapy for ovarian cancer in clinical trials progressing from advanced disease to patients with disease remaining at second look surgery and through basic research targeted at the enhancement of the efficacy of alkylating agents. In Project II, we investigate the detection of malignant contamination of the bone marrow and peripheral blood with neoplastic cells using immunologic methods and utilize pharmacologic and immunologic methods to remove these malignant cells from the marrow. In Project IIIA, we propose studies of new combination of cytokines and schedule to extend our observations of CSF primed peripheral blood progenitor cells in patients with breast cancer undergoing high dose chemotherapy and will use ex vivo expansion of stem-cell enriched progenitors with emly acting cytokines to provide cells for support after high-dose therapy and to study in detail the distribution of cytokines and their receptors. The program project is supported by cryopreservation, statistical and administrative cores.

本计划项目拨款申请适用于继续资助 PPG CA-47741 用于自体骨高剂量化疗研究 骨髓支持治疗乳腺癌和卵巢癌。该计划 包括四个项目和三项核心活动，这些活动高度重视 相互关联、依赖和互动。在项目 IA 中，我们建议 (1) 完成第四阶段的前瞻性随机比较试验 II 期乳腺癌根据第一次申请开始资助，并且 (2) 扩大大剂量化疗和自体骨髓的使用 通过三种方式提供支持：(a) 对患有以下疾病的患者进行高剂量治疗 原发性乳腺癌涉及 4 至 9 个腋窝淋巴结，并且 (b) 一项随机比较试验中仅患有骨疾病的患者； (c) 至 探索串联使用第二种高剂量化疗方案。 在项目 lB 中，我们评估了高剂量化疗对卵巢的作用 临床试验中的癌症从晚期疾病进展到患者 在复查手术和基础研究中仍有疾病存在 旨在增强烷化剂的功效。在 项目二，我们调查恶性污染的检测 使用免疫学方法检测骨髓和外周血中的肿瘤细胞 方法并利用药理学和免疫学方法去除这些 来自骨髓的恶性细胞。在项目 IIIA 中，我们建议研究 细胞因子和时间表的新组合以扩展我们的观察 脑脊液引发乳腺癌患者的外周血祖细胞 正在接受高剂量化疗的癌症将使用离体扩增 富含干细胞的祖细胞，具有直接作用的细胞因子，以提供 细胞在高剂量治疗后提供支持并详细研究 细胞因子及其受体的分布。该计划项目是 由低温保存、统计和管理核心支持。